InvestSMART

Island Pharmaceuticals Limited (ASX: ILA) - Announcements

- Current share price for ILA : $0.335

ASX company news and announcements for Island Pharmaceuticals Limited (ILA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Island Pharmaceuticals Limited (ILA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Island Pharmaceuticals Limited (ILA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Island Pharmaceuticals Limited (ILA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$99 Replacement - Change in substantial holding 27 Apr 2023 5:29PM $0.081 $0.335 risen by 316.15%
$99 Change in substantial holding 27 Apr 2023 2:38PM $0.081 $0.335 risen by 316.15%
$99 Quarterly Activity Report & Appendix 4C 27 Apr 2023 9:00AM $0.085 $0.335 risen by 294.12%
$99 Island submits responses to FDA questions for ISLA-101 17 Apr 2023 9:32AM $0.070 $0.335 risen by 378.57%
$99 Application for quotation of securities - ILA 13 Apr 2023 9:10AM $0.070 $0.335 risen by 378.57%
$99 Appendix 3Y - Albert Hansen 4 Apr 2023 4:26PM $0.070 $0.335 risen by 378.57%
$99 Notification of cessation of securities - ILA 4 Apr 2023 4:15PM $0.070 $0.335 risen by 378.57%
$99 Release of Securities from Escrow 3 Apr 2023 1:16PM $0.070 $0.335 risen by 378.57%
$99 Appendix 4D & Half-Year Financial Statements 23 Feb 2023 12:26PM $0.097 $0.335 risen by 245.36%
$99 Change in substantial holding 7 Feb 2023 2:16PM $0.140 $0.335 risen by 139.29%
$99 ILA receives additional FDA feedback on IND for ISLA 101 1 Feb 2023 9:46AM $0.150 $0.335 risen by 123.33%
$99 Quarterly Activity Report & Appendix 4C 30 Jan 2023 9:03AM $0.150 $0.335 risen by 123.33%
$99 Island receives FDA feedback on Phase 2a clinical study 20 Jan 2023 9:51AM $0.190 $0.335 risen by 76.32%
$99 ILA submits IND to US FDA for Phase 2a PEACH clinical trial 28 Dec 2022 9:08AM $0.190 $0.335 risen by 76.32%
$99 Notice of Change of Auditor 19 Dec 2022 4:14PM $0.170 $0.335 risen by 97.06%
$99 Island online investor briefing presentation 15 Dec 2022 9:18AM $0.170 $0.335 risen by 97.06%
$99 IRB approval received for ISLA101 Phase 2a clinical trial 15 Dec 2022 9:07AM $0.170 $0.335 risen by 97.06%
$99 ISLA101 drug product achieves stability milestone 15 Dec 2022 8:57AM $0.170 $0.335 risen by 97.06%
$99 Island investor briefing invitation 12 Dec 2022 11:29AM $0.175 $0.335 risen by 91.43%
$99 ISLA-101 trial update and investor presentation 5 Dec 2022 8:54AM $0.190 $0.335 risen by 76.32%
$99 Island to present at World Antiviral Congress 2022 29 Nov 2022 9:23AM $0.190 $0.335 risen by 76.32%
$99 Change in substantial holding 21 Nov 2022 8:36AM $0.200 $0.335 risen by 67.50%
$99 Results of AGM 17 Nov 2022 1:15PM $0.205 $0.335 risen by 63.41%
$99 Annual General Meeting MD Presentation 17 Nov 2022 8:53AM $0.220 $0.335 risen by 52.27%
$99 ILA granted key Canadian patent for ISLA-101 16 Nov 2022 9:00AM $0.190 $0.335 risen by 76.32%

326 - 350 of 459 results

Page 14 of 19

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.